U.S. Markets closed

How GlaxoSmithKline’s Vaccines Business Has Performed Recently

Mike Benson
How GlaxoSmithKline’s Vaccines Business Has Performed Recently

GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.